TG Therapeutics, Inc. (TG) operates as a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases.
The company has received approval…
Analysis
Middle-of-the-road
TG Therapeutics, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.
On valuation, the picture is attractive. The owner-earnings multiple stands at 14.7×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 2% a year, against analyst forecasts of 15%. The price, in other words, assumes less than the experts do.
Growth is moderate; the safety picture is adequate. The company scores 18/20 on our value-creation score: strong value creator.
Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Mar 202687
89
2026
All-time high
89
Jun 2026
All-time low
87
Mar 2026
Average rank
88
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
69
—
—
—
Price/Earnings
7
—
—
—
Price/Book
23
—
—
—
Dividend Yield
—
—
—
—
Value (overall)
31
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.